Multicenter Study of Endophthalmitis After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents

S. J. Driscoll; K. S. Klein, MD; M. Walsh; T. S. Hassan, MD; L. S. Halperin, MD; A. A. Castellarin, MD; D. Roth, MD; J. L. Prenner, MD

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

AdvancedSearch

Free

ARVO Annual Meeting Abstract | April 2009

Multicenter Study of Endophthalmitis After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents

S. J. Driscoll; K. S. Klein, MD; M. Walsh; T. S. Hassan, MD; L. S. Halperin, MD; A. A. Castellarin, MD; D. Roth, MD; J. L. Prenner, MD

Author Affiliations & Notes

S. J. Driscoll

Ophthalmology / Medical Student,
Robert Wood Johnson Medical School, New Brunswick, New Jersey
K. S. Klein, MD

NYU Medical School, New York, New York
M. Walsh

Ophthalmology, Associated Retinal Consultants, Royal Oak, Michigan
T. S. Hassan, MD

Ophthalmology, Associated Retinal Consultants, Royal Oak, Michigan
L. S. Halperin, MD

Ophthalmology, Retina Group of Florida, Boca Raton, Florida
A. A. Castellarin, MD

California Retina Consultants, Santa Barbara, California
D. Roth, MD

Ophthalmology,
Robert Wood Johnson Medical School, New Brunswick, New Jersey
J. L. Prenner, MD

Ophthalmology,
Robert Wood Johnson Medical School, New Brunswick, New Jersey

Investigative Ophthalmology & Visual Science April 2009, Vol.50, 6185. doi:

Abstract

Purpose: : To investigate the incidence of endophthalmitis after intravitrealinjection of anti-vascular endothelial growth factor (VEGF)agents.

Methods: : Retrospective chart review.

Results: : We identified 15 cases of presumed endophthalmitis out of 30329anti-VEGF injections (pegaptanib, bevacizumab and ranibizumab)over a one year time span. Mean time to diagnosis was 3.5 days.46% of cases were culture positive. 10 patients returned tobaseline vision, 2 lost between 3-5 lines of vision, 1 droppedfrom 20/30 to hand motions vision, and 2 became no light perception.

Conclusions: : This large multicenter study revealed a presumed endophthalmitisincidence of 0.049% in over 30000 injections. 67% of patientsreturned to baseline vision while 20% had very poor outcomes.

Keywords: endophthalmitis • vascular endothelial growth factor • injection

© 2009, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.

This feature is available to authenticated users only.

To View More...

You must be signed into an individual account to use this feature.